Table 3.

Summary of ongoing clinical trials for novel predictive biomarkers for targeted therapy.

Gene	Alteration	Drug	Eligible Patients	Trial Name	Treatment	Ref.
KRAS	G12C	AMG 510 (Sotorasib)	Previously treated, locally advanced, unresectable, or metastatic NSCLC	CodeBreak 200 NCT04303780 Phase 3	AMG 510 vs. Docetaxel	[142]
		MRTX849 (Adagrasib)	Previously treated for metastatic NSCLC	KRYSTAL-12 NCT04685135 Phase 3	MRTX849 vs. Docetaxel	[143]
	KRAS mutation in codons 12 or 13	Selumetinib + Docetaxel	Locally advanced or metastatic NSCLC	SELECT-1 NCT01933932 Phase 3	Selumetinib + Docetaxel vs. Placebo + Docetaxel	[144]
		Abemaciclib (LY2835219)	Stage IV NSCLC patients who have progressed after platinum-based chemotherapy	JUNIPER NCT02152631 Phase 3	Abemaciclib vs. Erlotinib	[145]
	G12V, G12C	Carboplatin + paclitaxel + bevacizumab	IIIB or stage IV NSCLC patients eligible for platinum-based chemotherapy and are chemotherapy naïve	NCT02743923 Phase 3	Carboplatin-paclitaxel-bevacizumab vs. Cisplatin-pemetrexed	[146]
FGFR1	FGFR1 amplification (>5 copies)	Dovitinib	Pretreated advanced SQC	NCT01861197 Phase 2	Dovitinib	[121]
	Aberrant signaling	E7080 + Carboplatin + Paclitaxel	Advanced or metastatic NSCLC	NCT0083281 9Phase 1	E7080 + Carboplatin+ Paclitaxel	[122]
		Pazopanib	Resectable stage I/II NSCLC	NCT0036767 9Phase 2	Pazopanib	[123]
		Nintedanib BIBF 1120	Stage IIIB/IV or recurrent NSCLC after the failure of first-fine chemotherapy	LUME-Lung 1 NCT00805194 Phase 3	Nintedanib + Docetaxel vs. Placebo + Docetaxel	[124]
DDR2	DDR2 mutations	MGCD516	Advanced solid tumor, including NSCLC	NCT02219711 Phase 1	MGCD516
HER2	exon 20 mutations	Afatinib	Pretreated patients with advanced NSCLC	NICHE NCT02369484 Phase 2	Afatinib	[147]
		Pyrotinib	Advanced non-squamous NSCLC patients who failed platinum-based chemotherapy	PYRAMID-1 NCT04447118 Phase 3	Pyrotinib vs. Docetaxel
		Pertuzumab+ Trastuzumab + Docetaxel	NSCLC patients harboring HER2 exon 20 mutation or insertion	NCT03845270 Phase 2	Pertuzumab+ Trastuzumab + Docetaxel
	HER2 mutations	Neratinib, temsirolimus	Advanced (stage IIIB) or metastatic (stage IV) NSCLC	NCT01827267 Phase 2	Neratinib or Neratinib + Temsirolimus	[148]
	HER2 mutations or overexpression	Trastuzumab deruxtecan (DS-8201a)	Unresectable and/or metastatic NSCLC	DESTINY-Lung01 NCT03505710 Phase 2	Trastuzumab deruxtecan (DS-8201a)	[149]